Glaucoma implant could replace daily eye drops
NCT ID NCT07641296
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a small ring placed in the eye that slowly releases the drug bimatoprost to lower eye pressure in people with glaucoma or ocular hypertension. The ring is implanted during a quick surgery and may work for up to 3 years. The trial includes 24 adults and compares two different doses of the ring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimatoprost drug ring system
What this could lead to
If it works, this could offer a long-lasting, implant-based way to control eye pressure in glaucoma patients, reducing the need for daily eye drops.
What could go wrong
This is a very early phase 1 trial with only 24 people. The implant requires surgery, and it's not yet known if it works better than standard treatments or if there are long-term risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••